Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 18.81% | 4.16% | 6.66% | 10.83% | -22.86% |
| Total Depreciation and Amortization | -5.04% | -1.97% | 0.80% | 2.71% | 14.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -85.78% | -82.87% | -80.46% | -82.83% | 238.00% |
| Change in Net Operating Assets | -105.48% | -132.40% | -54.37% | -13.27% | 136.98% |
| Cash from Operations | -33.52% | -58.57% | -17.55% | -13.22% | 11.55% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 86.66% | 392.57% | 38.35% | 18.50% | -31.50% |
| Total Debt Repaid | 10.01% | 11.37% | 92.75% | 92.90% | 91.48% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 99.02% | 565.78% | 3,031.84% | 1,234.09% | 813.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 87.03% | 101.25% | 108.75% | 96.44% | 70.39% |
